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Abstract
Introduction Norepinephrine (NE) has a regulatory role in
human attention.
Objective To examine its role in emotional modulation of
attention, we used an attentional blink (AB) paradigm, in
the context of psychopharmacological manipulation, where
targets were either emotional or neutral items.
Results and discussion We report behavioural evidence that
β-adrenergic blockade with propranolol impairs attention
independent of target valence. Furthermore, this effect is
centrally mediated as administration of the peripheral β-
adrenergic antagonist nadolol did not impair attention. By
contrast, increasing NE tone, using the selective NE
reuptake inhibitor reboxetine, improves detection of emo-
tional stimuli.
Conclusion In line with theoretical and animal models,
these findings provide human behavioural evidence that the
adrenergic system has a modulatory influence on selective




Norepinephrine (NE) is a monoaminergic neurotransmitter
released by ascending projections of the locus coeruleus
(LC). NE plays a critical role in regulating cortical function
and is implicated in the pathophysiology of major psychi-
atric disorders, such as depression, schizophrenia, and more
recently attention deficit disorder (Beane and Marrocco
2004; Pliszka et al. 1996). While the role of NE system in
arousal is well established (Jouvet 1969;R o b i n s o na n d
Berridge 1993), recent data from animal models suggest a
role in facilitating processing of relevant, or salient,
information (Berridge and Waterhouse 2003;Yu and Dayan
2005). Electrophysiological studies in monkeys indicate that
there are two modes by which LC activity modulates
attention (Aston-Jones and Cohen 2005). Phasic LC neuro-
nal activation is evoked by salient or goal-relevant stimuli
during vigilance tasks, a response positively associated with
outcomes in task-related decisions and coupled with highly
accurate responses (Aston-Jones et al. 1994). Phasic
responses occur against the background of, and are in turn
modulated by, tonic LC activity that correlates with general
arousal levels (Aston-Jones et al. 1991, 1994).
We have recently shown (Strange and Dolan 2007) that
the cortical circuitry engaged by salient stimuli is inhibited
by pharmacological blockade of the noradrenergic system.
Specifically, we demonstrated a role for β-adrenergic
receptors in this process. This differs from previous
psychopharmacological experiments addressing NE modu-
lation of attention, which have typically examined the
effects of α2-adrenergic receptor agonists such as clonidine
(Coull et al. 2001). Subjects receiving clonidine, compared
to placebo, are impaired at target discrimination (Clark et
al. 1986) but also report subjective withdrawal and
difficulties with concentration. Clonidine acts on presynap-
tic α2-adrenergic auto-receptors to inhibit NE release; thus,
clonidine-induced impaired attention may reflect decreased
arousal or, due to presynaptic inhibition of NE release,
decreased stimulation of predominantly postsynaptic α1-o r
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antagonist propranolol is non-sedating (Harmer et al.
2001), its administration enables investigation of the
adrenergic role in attention without sedation and localising
specific attentional effects to a specific receptor subtype.
To investigate the noradrenergic modulation of human
attention, we used a modification of the RSVP attentional
blink (AB) paradigm in which subjects view a rapid
sequence of visual stimuli (RSVP; Raymond et al. 1992)
with a task requirement being to identify embedded targets.
A classical finding using this type of manipulation is that
identifying a first target stimulus (T1) causes transient
impairment in detecting a subsequently presented second
target (T2), an effect reduced with increasing temporal lag
between the two targets. This paradigm allowed us to
investigate how emotional stimuli modulate the allocation
of limited attentional resources in time. Thus, the present
study was designed to investigate the time dynamic of the
interaction between attention and emotion.
Of particular interest to the study of a adrenergic role in
attentional control is the recent finding that the AB can be
modulated by the emotional significance of stimuli. The
crucial observation in this study is that an arousing T2
stimulus is detected more often than a neutral T2 (Anderson
and Phelps 2001), an effect abolished by amygdala damage
(Anderson and Phelps 2001). These observations parallel
those seen during studies of human episodic memory where
memory is enhanced for emotional events, an effect not
seen in patients with amygdala lesions (Cahill et al. 1994;
Strange et al. 2003). Enhanced emotional memory effect are
abolished by propranolol (Cahill et al. 1994; Strange et al.
2003), which leads to an hypothesis that the emotional
modulation of the AB would also be abolished by β-
adrenergic blockade. However, in light of our finding
(Strange and Dolan 2007) that propranolol modulates the
cortical circuitry involved in salience detection, the effects
of propranolol on the AB might be more complex, i.e.,
there may be a generic effect of β-adrenergic blockade on
T2 detection.
Thus, within the current RSVP task, each trial consisted
of 15 words, 2 targets (bright green) and 13 distractors
(black), presented for 130 ms each and immediately
followed by the subsequent stimulus (Fig. 1). In half the
trials, the T2 stimuli consisted of arousing words (e.g. rape
and incest) and in the other half neutral words. Task
difficulty was manipulated by introducing different tempo-
ral lags. Before the first experiment, subjects received either
propranolol or placebo in a double-blind fashion (Experi-
ment 1). In Experiment 2, subjects performed a more
difficult version of the task, to address possible ceiling
effects seen in Experiment 1. As an additional manipulation,
subjects were randomised to receive either placebo, propran-
olol or the selective norepinephrine reuptake inhibitor
(SNRI) reboxetine. Thus, this experimental design enabled
us to investigate the effects of adrenergic modulation, either
inhibitory or facilitatory, on an attention paradigm in which
both the salience and valence of the T2 target was
manipulated. In a third experiment, we tested for the
contribution of peripheral β-blockade to the attentional
effects seen with propranolol by administering nadolol, a
β-blocker that does not cross the blood–brain barrier (BBB).
Experiment 3 also included a group that received a lower
dose of propranolol to determine whether modulatory effects
observed in Experiments 1 and 2 were dose dependent.
Materials and methods
Ninety-six healthy right-handed native English-speaking
subjects took part in our studies. All volunteers gave
informed consent, were free of neurological, psychiatric
and physical illness and had not been on any medication for
>3 months. The study was approved by the National
Hospital for Neurology and Neurosurgery and the Institute
of Neurology Joint Research Ethics Committee.
Fig. 1 Schematic diagram of the AB task. Each trial consisted of 15
words [2 targets (bright green) and 13 distractors (black)] each
presented for 130 ms (Experiment 1) or 110 ms (Experiment 2) and
immediately followed by the subsequent stimulus. In half the trials,
the T2 stimuli consisted of an arousing word (e.g. rape and incest) and
in the other half T2 were neutral words (e.g. pepper and omit). The
neutral and emotional stimuli were matched for average word length,
word frequency and interletter frequency. Order or presentation of
emotional and neutral trials was random. The temporal lag between
the first target (T1) and the second target (T2) was variable. At early
lag (<500 ms, SOA), the detection of target T2 is more susceptible to
the attentional blink compared with late lag (>500 ms, SOA). The
subjects’ task was to monitor the RSVP stream and report both
coloured green targets (T1 and T2) by typing them at the end of a
stimulus sequence
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Subjects In a double-blind experimental design, 36 subjects
[18 male, mean age (SD)=24.2 (3.9); 18 female, mean age=
23.1 (4.0)] received either a 40-mg oral dose of propranolol
hydrochloride (a β1a n dβ2 adrenergic receptor antagonist)
or a 100 mg oral dose of ascorbic acid (placebo pill). Drug
allocation, in this and subsequent experiments, was balanced
for gender. In view of the kinetics of propranolol’sp e a k
plasma concentration (1–2 h), the attentional blink task
commenced 90 min after drug administration. Blood
pressure (BP) was measured immediately before drug
administration (time 0 min) and the attention task (time
+90 min).
Stimuli We used a modification of the RSVP paradigm
(Anderson and Phelps 2001; Raymond et al. 1992) where
each trial consisted of 15 words [2 targets (bright green)
and 13 distractors (black)] each presented for 130 ms and
immediately followed by the subsequent stimulus (Fig. 1).
Six trial lags were introduced from lag 2 [1 distractor
presented between the two targets (T1-T2) SOA=260 ms]
to lag 7 [6 distractors presented between the two targets
(T1–T2) SOA=910 ms]. In half the trials, the T2 stimuli
consisted of an arousing word (e.g. rape and incest), and in
the other half, T2 were neutral words (e.g. pepper and
omit). The neutral and emotional stimuli were matched for
average word length, word frequency and inter-letter
frequency. The presentation order of emotional and neutral
trials was random. The subjects’ task was to monitor the
RSVP stream and report both coloured green targets (T1
and T2) by typing them at the end of a stimulus sequence
(trials in which a T1 target was not reported correctly were
discarded from the analysis of T2 effects).
Statistics Following the analysis of Anderson and Phelps
(Anderson and Phelps 2001), data were segregated into
early (lags 2–3, 260–390 ms) and late lag (lags 6–7, 780–
910 ms). We performed a 2×2×2 drug (propranolol 40 mg,
placebo) × valence of T2 stimulus (emotional, neutral) ×
lag (early vs late) analysis of variance (ANOVA). In this
and all subsequent experiments, ANOVAs were followed
by post-hoc two sample unequal variance t tests to test for
simple effects.
Experiment 2
Subjects In a double-blind experimental design, 30 subjects
[15 male, mean age (SD)=24.7 (2.8); 15 female, mean age=
23.3 (3.1)] were allocated to one of three equal sized groups
and received either a 40-mg oral dose of propranolol, a 4-mg
oral dose of reboxetine methansulphonate (a selective
norepinephrine reuptake inhibitor) or a 100-mg oral dose of
ascorbic acid (placebo pill). In view of the kinetics of
propranolol and reboxetine’s peak plasma concentration (1–
2 and 1.5 h, respectively), the attentional blink task
commenced 120 min after drug administration. One subject
in the propanolol group was excluded from further analysis
because behavioural performance was more than two
standard deviations below the group average.
Stimuli The task used was identical to Experiment 1 except
for two critical modifications; the time of the stimulus
presentation was decreased from 130 ms in Experiment 1 to
110 ms, and targets were separated by six different time
lags ranging from one to nine distractors presented between
the two targets (lags 2–3–4–7–8–9) [e.g. lag 2 (T1–T2)
SOA=220 ms; lag 9 (T1–T2) SOA=990 ms].
Statistics Data were collapsed into early (lags 2–3–4, 220–
440 ms) and late lags (lags 7–8–9, 770–990 ms) and a drug
(propranolol 40 mg, reboxetine, placebo) × T2 valence
(emotional, neutral) × lag (early, late) 3×2×2 ANOVA
performed. For each drug group, we also performed a 2×2
drug (drug, placebo) × T2 valence (emotional, neutral)
ANOVA.
Experiment 3
Subjects In a double-blind experimental design, 30 subjects
[15 male, mean age (SD)=25.2 (3.7); 15 female, mean age=
25.5 (3.9)] were allocated to one of three equal size groups
and received either a 20-mg oral dose of propranolol, a 40-
mg oral dose of nadolol (a β1a n dβ2 adrenergic receptor
antagonist that does not cross the BBB) or a 100 mg oral
dose of ascorbic acid (placebo pill). In view of the kinetics of
propranolol and nadolol peak plasma concentration (1–2h ) ,
the attentional blink task commenced 120 min after drug
administration. One subject in the propanolol group was
excluded from further analysis because performance was
more than two standard deviations below the group average
(task outlier). Three subjects in the placebo group were
excluded (two on the grounds of being task outliers and one
on subsequent disclosure of not being a native English
speaker).
Stimuli The task used was identical to Experiment 2 using
the same equipment.
Statistics After exclusion criteria, the size of the placebo
group was drastically reduced (seven subjects). Thus, to
retain sufficient statistical power, we collapsed data from
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Experiment 2. Data were collapsed into early (lags 2–3–4,
220–440 ms) and late lags (lags 7–8–9, 770–990 ms) and
separate analyses performed for each drug group (propano-
lol 20 mg, nadolol 40 mg) vs placebo, i.e. separate group
(drug × placebo) × T2 valence (emotional, neutral) × lag
(early, late) 2×2×2 ANOVAs.
Results
Experiment 1 This psychopharmacological experiment
demonstrated that β-adrenergic blockade by propranolol
significantly impaired detection of T2 targets independently
of their emotional valence (i.e. emotional and neutral; see
Fig. 2). In both placebo and drug groups, we observed
enhanced reporting of emotional, relative to neutral, T2
stimuli and a proportional increase in detecting both types
of T2 stimuli with increasing T1-T2 lag, in agreement with
previous observations (Anderson and Phelps 2001). In the
placebo group, the percentage of T2 correctly reported at
early lag was for the neutral T2 (NT2) 86.99%±2.42 and
for the emotional T2 (ET2) 93.93%±1.43. At late lag, these
values increased to NT2=92.62%±1.28 and ET2=95.8%±
1.13. Conversely, in the 40-mg propranolol group, the
percentage of T2 correctly reported at early lag was NT2=
80.69%±1.90 and ET2=91.26%±1.93; performance at late
lag increased to NT2=88.18%±1.90 and ET2=93.84%±
1.47.
A drug (propranolol, placebo) × T2 valence (neutral,
emotional) × lag (early, late) 2×2×2 ANOVA yielded
significant main effects of treatment [F(1,34)=4.98, P<
0.05], T2-valence [F(1,34)=51.31, P<0.0001] and lag
[F(1,34)=26.33, P<0.0001]. In line with the observation of
Anderson and Phelps that affective modulation of the
attentional blink is most pronounced at early lags, we
demonstrated a lag × T2-valence interaction significant at
trend level [F(1,34)=3.72 P=0.062). Critically, there was no
significant interaction between T2-valence and drug manip-
ulation [F(1,34)=2.65, P=0.29] indicating that a propranolol
effect was not influenced by T2 target valence (Fig. 2). The
simple effect of group (placebo, propranolol) on T2
reporting was significant for neutral T2 [t(1,19)=2.04, P<
0.05 one-tailed] but not for emotional T2 [t(1,19)=1.13, P=
0.13].
Furthermore, no significant interaction was found be-
tween lags (early, late) and drug manipulation (propranolol,
placebo) [F(1,34)=0.51, P=0.476) indicating that the effect
of propranolol is present across all lags. Figure 2c shows
Fig. 2 Behavioural results of
Experiment 1. Subpanels a and
b show the percentage (%) of T2
stimuli that are correctly
reported for each T1–T2 tempo-
ral lag for a placebo and b
propranolol (40 mg) groups. In
both groups, T2 detection
improves with increasing tem-
poral lags, and is significantly
higher for emotional T2 (red
squares) compared with neutral
T2 (blue diamonds). The ad-
ministration of propranolol sig-
nificantly impairs T2 detection
independently of the arousal
content of the stimuli. c Im-
paired emotional (red lines) and
neutral (blue lines) T2 detection
produced by propranolol
(dashed lines) relative to place-
bo (solid lines) is more marked
at early lags (260–390 ms,
SOA), when attentional demand
is higher, compared with late
lags (780–910 ms, SOA). In
particular, the effect of the
propanolol on the detection of
neutral target was most dramatic
at lag 2 where the AB is known
to be maximal
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neutral T2 for early (260–390 ms, SOA) and late lags (780–
910 ms, SOA). Importantly, performance on T1 target
detection was not statistically different between placebo
(96.27%) and propranolol (96.18%) groups [t(1,19)=0.17,
P>0.05 one-tailed independent t test].
As seen in Fig. 2, performance in both placebo and drug
groups at late lags approached ceiling levels, which may
have obscured differential effects at these later lags. Thus,
in Experiment 2, we reduced the interstimulus interval,
making T2 detection more difficult. Removing this ceiling
effect enabled us to test the additional hypothesis that
increasing NE levels, with the SNRI reboxetine, would
enhance T2 detection.
Finally, the mean BP at the time of placebo/drug (0 min)
administration for the placebo group was 90 mmHg and at
the start of the experiment (+90 min) was 88.5 mmHg
[t(1,17)= 0 . 9 5P = 0 . 3 5t w o - t a i l e dp a i r e dt test]. For the
propranol group at 0 min was 86.2 mmHg and showed a
significant reduction at (+90 min) 81.9 mmHg [t(1,17)=2.16
P<0.05 two-tailed paired t test].
Experiment 2 Three different drug groups (placebo, pro-
pranolol and reboxetine) performed an attentional blink task
identical to Experiment 1 except for a reduction in stimulus
presentation time from 130 to 110 ms and a subtle change
in lag range. This experiment confirms the previous finding
(from Experiment 1) of a propranolol-induced impaired
detection of T2 targets, independently of whether these are
emotional or neutral stimuli. It also demonstrates that
reboxetine selectively boosts the detection of emotional
T2 with no effect on the neutral T2 (Fig. 3). In the placebo
group, the percentage of T2 correctly reported at early lag
was NT2=64.02%±4.67 and ET2=74.26%±5.65, and at
late lag NT2=77.87%±4.56 and ET2=84.5%±4.99. In the
40 mg propranolol group, the percentage of T2 correctly
reported at early lag was NT2=46.1%±5.28 and ET2=
61.6%±5.93 conversely at late lag NT2=62.68%±7.69 and
ET2=70.48%±7.62. In the reboxetine group, the percent-
age of T2 correctly reported at early lag was NT2=62.8%±
3.65 and ET2=82.64%±4.18 at late lag NT2=80.95%±
2.05 and ET2=90.23%±1.92.
Figure 3c shows the percentage (%±SE) of correctly
reported emotional (E) and neutral (N) T2 for early
(220–440 ms, SOA) and late lags (770–990 ms, SOA). A
drug (placebo, propranolol, reboxetine) × T2 valence
(neutral, emotional) × lag (early, late) 3×2×2 ANOVA
yielded a significant main effect of drug [F(1,27)=5.44,
P<0.01], T2-valence [F(1,27)=73.8, P<0.0001] and lag
[F(1,27)=93.54, P<0.0001]. The three-way interaction of
drug × T2-valence × lag was also significant [F(2,27)=3.46,
P<0.05].
To investigate the effects of drug relative to placebo, we
performed two further 2×2×2 ANOVAs. The effect of
propranolol in a drug (placebo, propranolol) × T2-valence
(neutral, emotional) × lag (early, late) 2×2×2 ANOVA
yielded a significant main effect of drug manipulation
[F(1,18)=4.58, P<0.05], T2-valence [F(1,18)=24.87, P<
0.0001] and lag [F(1,18)=86.51, P<0.0001]. The interac-
tion between T2-valence and drug manipulation was not
significant [F(1,18)=0.62, P=0.44]. The simple effects of
group (placebo, propranolol) on T2 detection was signifi-
cant for neutral T2 [t(1,19)=2.53, P<0.01) and at trend level
for emotional T2 [t(1,19)=1.53, P=0.07]. These data
replicate the results of Experiment 1, confirming that
propranolol impairs T2 detection independently of T2
emotional valence. As in Experiment 1, the degree of
affective modulation was most pronounced at early lags,
evident in a significant interaction of lag × T2-valence
[F(1,18)=6.59, P<0.05]. Again, no significant interaction
was found between lags (early, late) and drug manipulation
(propranolol, placebo) [F(1,18)=0.05, P=0.862]. Finally, in
this more difficult version of our task, T1 detection is
impaired in the propranolol group relative to placebo [82.13
vs 89.28% correct, respectively; t(1,18)=1.84, P<0.05 one-
tailed independent-samples t test].
By contrast, reboxetine evoked a selective enhancement
in emotional T2 detection. A drug (placebo, reboxetine) ×
T2 valence (neutral, emotional) × lag (early, late) 2×2×2
ANOVA yielded a significant main effect of T2 valence
[F(1,18)=107.89, P<0.0001] and lag [F(1,18)=54.39, P<
0.0001], but the main effect of reboxetine relative to
placebo was not significant [F(1,18)=0.57, P=0.46]. How-
ever, the interaction between T2-valence and drug manip-
ulation was significant [F(1,18)=10.61, P<0.005). The
simple effect of group (placebo, reboxetine) on T2
detection was not significant for neutral T2 [t(1,19)=0.44,
P=0.66] and was at trend level for emotional T2 [t(1,19)=
1.54, P=0.07]. These data demonstrate that enhanced NE
levels selectively improves detection of an emotional T2
stimulus with no effect on neutral T2. Again, detection of
emotional relative to neutral T2 stimuli was greatest at early
lags for both groups indexed by a significant lag × T2-
valence [F(1,18)=22.8, P<0.001] interaction. By contrast, a
lag (early, late) × drug manipulation (reboxetine, placebo)
interaction was not significant [F(1,18)=0.036, P=0.852],
indicating that the behavioural effect of reboxetine is
present across all lags. [t(1,17)=0.95, P=0.35 two-tailed
paired t test).
The mean BP at the time of placebo/drug (0 min)
administration for the placebo group was 90.9 mmHg and
showed a significant reduction at (+90 min) 82.9 mmHg
[t(1,9)=2.79, P<0.05 two-tailed paired t test]. For the
reboxetine group at (0 min) was 91.3 mmHg and showed
a non-significant reduction at (+90 min) 90.4 mmHg
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propranolol group, the mean BP at (0 min) was 85.1 and
showed a significant reduction at (+90 min) 78.9 mmHg
[t(1,9)=3.97, P<0.005 two-tailed paired t test].
Experiment 3 To further investigate the effects of propran-
olol, we conducted a third experiment in which three
different drug groups (placebo, nadolol 40 mg and
propranolol 20 mg) performed the AB task identical to
Experiment 2. The first drug group received 40 mg of
nadolol, a beta blocker with a the same mechanism of
action of propranolol (i.e. selective blockers of β1 and β2
adrenergic receptors) but that critically does not pass the
BBB (Hardman et al. 2001). This manipulation controlled
for the potential contribution of peripheral β-blockade to
the attentional effects observed with propranolol. The
second group received a dose of propranolol (20 mg) that
was half that used in Experiments 1 and 2. This treatment
was aimed at determining whether a lower dose of
propranolol would result in an attentional effect that was
specific for target valence. As shown in Fig. 4, correct T2
detection at early lag in the placebo group was NT2=
59.19%±3.44andET2=75.32%±3.58,andatlatelagNT2=
76.45%±3.13 and ET2=86.68%±3.21. In the 20 mg pro-
pranolol group the percentage of T2 correctly reported at
early lag was NT2=65.40%± 6.40 and ET2=78.20%±6.31,
whereas at late lag NT2=80.43%±5.02 and ET2=87.62%±
4.27. In the 40 mg nadolol group, the percentage of T2
correctly reported at early lag was NT2=62.24%±4.76 and
ET2=76.82%±5.57, and at late lag NT2=76.59%±4.08 and
ET2=88.07%±3.69.
Thus, T2 detection did not differ between nadolol and
placebo groups (Fig. 4). The drug (placebo, nadolol) × T2
Fig. 3 Behavioural results of Experiment 2. Subpanels a–c show the
percentage of T2 stimuli that are correctly reported for each T1–T2
temporal lag respectively in the placebo, reboxetine and propranolol
groups. In all groups, T2 detection improved with increasing temporal
lags and is significantly enhanced for emotional (red squares) relative
to neutral (blue diamonds) T2 detection. b As in Experiment 1,
propranolol significantly impairs T2 detection independently of
arousal. c Conversely, reboxetine significantly enhances detection of
emotional T2 with no effect on neutral T2. d T2 target detection in
placebo (solid lines), propranolol (small dashed lines) and reboxetine
(large dashed lines) groups on early lag (220–440 ms, SOA), when
the attentional demand is higher, compared with late lags (770–
990 ms, SOA) for emotional (red lines) and neutral (blue lines)T 2
stimuli
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ANOVA yielded a significant main effect of T2 valence
[F(1,25)=89.16, P<0.0001] and lag [F(1,25)=12.45, P<
0.005]), but no significant main effect of drug relative to
placebo [F(1,25)=0.06, P=0.80] or drug × T2-valence
interaction [F(1,25)=1.48, P=0.23] (Fig. 4). These results
confirm that the modulatory effects of propranolol observed
in Experiments 1 and 2 are due to central, and not
peripheral, effects.
Performance in the low dose propanolol group (20 mg)
was equivalent to that of the placebo group. The drug
(placebo, propanolol low dose 20 mg) × T2 valence
(neutral, emotional) × lag (early, late) 2×2×2 ANOVA
yielded a significant main effect of T2 valence [F(1,24)=
49.33, P<0.0001] and lag [F(1,24)=68.99, P<0.0001].
Although the low dose propranolol group (20 mg) per-
formed the task slightly better than the placebo group, this
difference was not statistically significant [main effect of
drug relative to placebo F(1,24)=0.42, P=0.52]. Critically,
there was no significant interaction between drug and T2-
arousal [F(1,24)=1.08, P=0.31] (Fig. 4). Thus, only the
higher propranolol dose (40 mg) impairs target detection,
an effect that is independent of target arousal content. A
lower propranolol dose does not impair detection of neutral
or emotional T2 detection.
The mean BP at the time of placebo/drug (0 min)
administration was for the placebo group was 90.5 mmHg
and showed a non-significant reduction at (+90 min)
86.0 mmHg [t(1,9)=1.8, P=0.102 two-tailed paired t test].
For the nadolol group at (0 min) was 90 mmHg and showed
a non-significant reduction at (+90 min) 88.6 mmHg [t(1,9)=
0.4, P= 0 . 6 9t w o - t a i l e dp a i r e dt test]. Finally, in the
propranolol group, the mean BP at (0 min) was 92.3 and
showed a significant reduction at (+90 min) 85.8 mmHg
[t(1,9)=2.79, P<0.05 two-tailed paired t test].
Discussion
The critical new observation we report is that β-adrenergic
blockade by propranolol (40 mg) impairs detection of T2
stimuli regardless of the emotional arousal of these stimuli
Fig. 4 Behavioural results of Experimental 3. Subpanels a–c show the
percentage of T2 stimuli that are correctly reported for each T1–T2
temporal lag respectively in the placebo, nadolol and propranolol low
dose (20 mg) groups. In all groups, T2 detection improved with
increasing temporal lags and is significantly enhanced for emotional
(red squares) relative to neutral (blue diamonds) T2 detection. Both
propanolol 20 mg (b) and nadolol 40 mg (c) do not show significant
differences from the placebo group. d T2 target detection in placebo
(solid lines), nadolol 40 mg (small dashed lines) and propanolol 20 mg
(large dashed lines) groups on early lag (220–440 ms, SOA), when the
attentional demand is higher, compared with late lags (770–990 ms,
SOA) for emotional (red lines) and neutral (blue lines)T 2s t i m u l i
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manipulation of the adrenergic system affects the AB. We
note in this regard that a recent study found no effect of
clonidine on neutral T2 detection (Nieuwenhuis et al.
2007). The robustness of our reported β-adrenergic effect
is evident in a replication within Experiment 2. Further-
more, these data also replicate previous observations
regarding emotional modulation of the attentional blink
(Anderson and Phelps 2001). Specifically, placebo and drug
groups, in Experiments 1 and 2, showed enhanced T2
detection with increasing T1–T2 lag for both emotional and
neutral T2, while emotional T2 stimuli were more frequent-
ly detected than neutral T2, an effect more pronounced at
early lags.
A recent comprehensive account of the role of NE in
attention is derived from monkey electrophysiological
experiments, which indicate two modes of LC activity
(Aston-Jones and Cohen 2005). Phasic LC neuronal
activation is evoked by salient or goal-relevant stimuli
during vigilance tasks (Aston-Jones et al. 1994). Phasic
responses are evoked against the background of, and in
turn modulated by, tonic LC activity that correlates with
general arousal levels (Aston-Jones et al. 1991;A s t o n -
Jones et al. 1994). Whereas the LC phasic response itself
is relatively brief in duration (typically of 50–100 ms), the
ensuing neuromodulatory effects of NE on target cortical
areas are known to be sustained relative to the LC phasic
response.
One recent hypothesis regarding the neurobiological
underpinnings of the attentional blink suggests that it is a
product of the temporal dynamics of the LC–NE system
(Nieuwenhuis et al. 2005). Although NE may potentiate
processing in cortical areas, local NE release within LC is
thought to be auto-inhibitory, due to effects of NE at
presynaptic and dendritic α2 autoreceptors (Egan et al.
1983; Washburn and Moises 1989; Williams et al. 1985).
This autoinhibition results in a refractory-like period after a
LC phasic response, during which a subsequent LC phasic
discharge is rarely observed (Aston-Jones et al. 1994; Usher
et al. 1999). This refractoriness peaks at approximately 50–
100 ms after the LC phasic response, typically 200–250 ms
after the eliciting stimulus, and usually lasts 200 ms or until
about 400–450 ms post-stimulus. The length of the
refractory period coincides with the T1 and T2 temporal
lag in which the blink for the second stimulus T2 is most
marked (Nieuwenhuis et al. 2005). Thus, this formulation
predicts an effect of NE modulation on both emotional and
neutral T2 detection.
Our behavioural effects can be explained via an
extension of theaforementioned AB–NE model (Nieuwenhuis
etal.2005) in which we also manipulated the salience level of
the T2 target (arousing or neutral). Previous studies demon-
strate that arousing stimuli presented in different modalities
induce a robust phasic discharge of NE neurons in LC
(Aston-Jones and Bloom 1981; Foote and Morrison 1987).
Thus, the enhanced detection of emotional relative to neutral
T2 stimuli, demonstrated by Anderson and Phelps
(Anderson and Phelps 2001) and replicated here in
Experiments 1 and 2, can be attributable to an increase
in phasic NE release elicited by emotional, relative to
neutral, stimuli. Propranolol has been demonstrated to
reduce the phasic response elicited by novel stimuli in rats
(Kitchigina et al. 1997). The effects we report after
propranolol administration may consequently be explained
in terms of a reduced impact of LC phasic response to
targets. A critical observation in our data is that propran-
olol-treated subjects show impaired T2 detection, relative
to placebo, for both neutral and emotional T2. Impor-
tantly, emotional T2 items, eliciting an increase in NE
release, are still detected more frequently than neutral T2
even in the presence of propranolol. According to the
model we propose, the behavioral effect in target detection
is relative to the magnitude of NE release, assumed to be
larger for an arousing T2. Note that our task required
subjects to report both T1 and T2 stimuli correctly. The
NE–AB hypothesis (Nieuwenhuis et al. 2005)s t a t e st h a t
initial T1 detection is mediated by phasic LC activity, with
the subsequent LC refractory period leading to impaired
T2 detection. If propranolol inhibits phasic LC activity, it
f o l l o w st h a tT 1d e t e c t i o ns h o u l da l s ob ei m p a i r e db yb e t a -
blockade. In Experiment 2, in which an increase in task
difficulty prevented T1 detection ceiling effects, we
indeed showed a significant impairment for T1 detection
for the propranolol compared with the placebo group.
Previous evidence (Jolicoeur 1999) provides an interpre-
tation that the increased difficulty in T1 detection under
propranolol may also contribute to the increased AB
magnitude that is independent of T2 emotionality, as
demonstrated in this study.
One of the aims of Experiment 3 was to determine
whether a lower dose (20 mg) of propranolol would yield
arousal-specific effects on T2 detection. In other words, we
tested whether less β-adrenergic blockade could be suffi-
cient to abolish enhanced detection of emotional T2 targets,
without affecting neutral T2 detection. We did not,
however, observe any difference in T2 detection for either
neutral or emotional targets between the propranolol 20 mg
group and placebo. Experiment 3 also served to demon-
strate that administration of nadolol, a peripherally acting
β-adrenergic antagonist, has no effect on T2 detection, thus
indicating that the attentional effects of propanolol are
centrally mediated.
In addition to demonstrating attentional impairment
evoked by blocking the β-adrenergic system, administra-
tion of a SNRI in Experiment 2 also enabled examination of
the attentional effects of increased NE concentration at the
134 Psychopharmacology (2008) 197:127–136synaptic level. We provide evidence for reboxetine-evoked
enhanced attention, which, in contradistinction to the
impairment observed with propranolol, is dependent on
the emotional salience of the target. That reboxetine failed
to improve neutral T2 detection accords with previous data
showing no effect of reboxetine on a neutral continuous
performance attention task (Plewnia et al. 2006).
Reboxetine-induced enhanced emotional T2 detection
can potentially be explained in terms of the NE–AB
hypothesis (Nieuwenhuis et al. 2005). Previous studies
demonstrate increased concentration of cortical NE, partic-
ularly in the frontal cortex, after acute reboxetine adminis-
tration (Sacchetti et al. 1999). By contrast, in the LC, NE
reuptake inhibitors attenuate the firing activity of LC–NE
neurons via α2-adrenergic autoreceptor overactivation
(Beique et al. 2000; Kasamo et al. 1996; Lacroix et al.
1991). Thus, SNRIs mediate two opposite effects: at a
cortical level, they potentiate attentional gain; but at the
level of LC, SNRIs increase the refractory period via
presynaptic α2 receptors. These two NE influences could
potentially produce opponent effects on T2 detection
involving facilitation and impairment in the AB task. In
Experiment 2, we found that reboxetine selectively boosted
detection of emotional T2 stimuli with no effect on neutral
T2. These findings can be reconciled with the proposed
model if, for neutral T2 detection, the facilitatory and
impairing effects of reboxetine are in relative equilibrium,
resulting in no net effect on neutral target detection.
Conversely, the boost in NE elicited by the arousing T2
positively interacts with this state of equilibrium thereby
significantly improving target detection for emotional
items.
Enhanced processing of emotional stimuli might also, in
theory, result in a lowered perceptual threshold for the
arousing stimuli that arises epigenetically (Weinberger
1999). This framework predicts that propranolol would
not have a selective effect on the perception of emotional
stimuli, as the lower threshold for processing arousing
stimuli is ‘hard-wired’ and therefore not dependent on
phasic release of noradrenaline. This model could explain
the findings from Experiments 1 and 2 showing that
propranolol does not have a selective effect on emotional
T2 processing.
Our results show a dissociation in the effects of
propranolol on attention from effects previously reported
on episodic memory (Strange et al. 2003). Whereas the
effect of propranolol is selective for the emotional
modulation of memory, we demonstrate for the first time
in humans (Experiments 1 and 2) that engagement of β-
adrenergic receptors in the central nervous system is
essential for optimal target detection independent of
stimulus arousal content. Moreover, we demonstrate that
the increase in NE levels (Experiment 2) selectively
improves detection of arousing stimuli. These attentional
effects of pharmacological manipulation of the NE system
in human subjects support and extend current theoretical
models of the role of NE in attention.
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